Rep. Gilbert Ray Cisneros, Jr. Purchases Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Vaxcyte, Inc. (NASDAQ:PCVX). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in Vaxcyte stock on July 16th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.

Vaxcyte Trading Down 1.1%

PCVX traded down $0.67 during midday trading on Tuesday, hitting $60.49. The company’s stock had a trading volume of 275,127 shares, compared to its average volume of 1,365,914. Vaxcyte, Inc. has a 52-week low of $30.81 and a 52-week high of $65.00. The firm has a 50-day moving average price of $58.29 and a two-hundred day moving average price of $56.27. The firm has a market cap of $9.00 billion, a P/E ratio of -7.94 and a beta of 1.22.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same quarter in the previous year, the business earned ($1.22) EPS. On average, equities analysts expect that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $86.00.

Insider Activity at Vaxcyte

In related news, CEO Grant Pickering sold 22,461 shares of the stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $52.50, for a total value of $1,179,202.50. Following the sale, the chief executive officer owned 474,703 shares of the company’s stock, valued at $24,921,907.50. This trade represents a 4.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harpreet S. Dhaliwal sold 17,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total value of $935,000.00. Following the transaction, the insider owned 76,756 shares of the company’s stock, valued at approximately $4,221,580. This represents a 18.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 121,873 shares of company stock valued at $6,671,730 in the last 90 days. 3.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vaxcyte

A number of institutional investors have recently made changes to their positions in PCVX. Corient Private Wealth LP grew its position in shares of Vaxcyte by 866.3% during the second quarter. Corient Private Wealth LP now owns 36,894 shares of the company’s stock worth $2,145,000 after buying an additional 33,076 shares in the last quarter. California State Teachers Retirement System raised its holdings in Vaxcyte by 5,915.2% in the second quarter. California State Teachers Retirement System now owns 8,186,622 shares of the company’s stock valued at $475,888,000 after acquiring an additional 8,050,522 shares in the last quarter. Readystate Asset Management LP raised its holdings in Vaxcyte by 332.5% in the second quarter. Readystate Asset Management LP now owns 156,090 shares of the company’s stock valued at $9,074,000 after acquiring an additional 120,000 shares in the last quarter. Nykredit A S bought a new position in Vaxcyte during the 2nd quarter valued at $1,235,000. Finally, B. Metzler seel. Sohn & Co. AG bought a new position in Vaxcyte during the 2nd quarter valued at $4,412,000. 96.78% of the stock is owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.